October 10, 2007 – Proteolix, Inc. and South Texas Accelerated Research Therapeutics (START) announced the enrollment of the first patient in a Phase 1 clinical trial to study Proteolix’s investigational drug, carfilzomib (PR-171)....
...After determining the maximum tolerated dose, additional patients will be enrolled in Phase 2 and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer... Proteolix's Press Release -
